VIEW MORENovel ACT-Discover liquid biopsy shows 30% increased sensitivity in detecting tumor DNA in blood
VIEW MORETwo studies published today in Nature and Nature Genetics compare the complete genome of more than 7,000 primary and metastatic tumours and describe the global genomic differences between them, as well as their interaction with the immune system
Latest News
22 May 2023
The power of three: triplet drug combination slows disease progression in patients with advanced kidney cancer
Published in The New England Journal of Medicine (1) results of the phase 3 COSMIC-313 trial show that the addition...
16 May 2023
VHIO’s Scientific Report 2022: Advancing cancer care through transformative team science
This year’s Scientific Report is themed Advancing cancer care through transformative team science. It celebrates VHIO’s model of multidisciplinary and...
16 May 2023
Novel ACT-Discover liquid biopsy shows 30% increased sensitivity in detecting tumor DNA in blood
Liquid biopsy is increasingly stepping up as a non-invasive approach in detecting and tracking circulating tumor DNA (ctDNA) in blood...
11 May 2023
Oniria Therapeutics closes €1.28 million seed funding round
The operation was led by the Botin Foundation Mind the Gap programme, with participation from BStartup of Banco Sabadell. The...
Research Programs
PRECLINICAL & TRANSLATIONAL RESEARCH
Cellular Plasticity and Cancer Group
Our group focuses on the interplay between cellular plasticity, stem cells and cancer. Cellular plasticity is recognized today as a critical feature of cancer cells that enables them to transit between different cellular states, including reversible transitions.
PRECLINICAL & TRANSLATIONAL RESEARCH
Growth Factors Group
We focus our research on mechanisms of resistance to targeted therapies and most importantly, how to overcome it by showing that breast cancers resistant to T-DM1, an antibody-drug conjugate ADC)- can be efficiently treated with the second generation ADC SYD985 (Nadal-Serrano et al.).
CORE TECHNOLOGIES
Cancer Genomics Group
VHIO’s Cancer Genomics Group serves as a Core Technology laboratory. We are also dedicated to translational research as well as the development of novel genomic tests.
PRINCIPAL RESEARCHERS
Events
Friday 2 June 23 - 12:00 PM
scientific-seminars Seminars
Ramon Alemany | Cancer Virotherapy with Oncolytic Adenoviruses
Tuesday 6 June 23 - 06:00 PM
Patients Severo Ochoa
Efectos secundarios. Hablamos de experiencias, compartimos realidades
Wednesday 14 June 23 - 11:00 AM
Patients
Diet and breast cancer. We discover how diet can help you improve symptoms and side effects
Monday 26 June 23 - 03:00 PM
Patients Severo Ochoa
¿Cómo abordar el cáncer renal? Una mirada integral
